Survival analysis indicated GBM patients with a high-risk score and IDH1-wild type had the worst results (Figure 5C), and in the non-mesenchymal subgroup, patients with a high-risk score had a shorter survival time than those with a low-risk score (Figure 5D). This evidence concerns the gene IDH1 and glioblastoma.